Astera Labs Just Got a $275 Target-But the Neutral Rating Says the Easy AI Connection Money May Be Gone

Susquehanna raised the target, but not its view on the stock

Susquehanna's upgrade to Astera Labs' price target is good operating news, not a clean buy signal. The firm lifted its target from $230 to $275 while keeping a "neutral" rating, and that $275 target still implies roughly 8.24% downside from the stock's current price.

That progression matters. Just last May, Susquehanna raised its target from $155 to $230 on the same Neutral rating before moving it again to $275. The business case has clearly improved faster than the stock recommendation has turned bullish.

With a Neutral rating and a higher target, the message is fairly straightforward: there is still upside, but it now looks more dependent on execution and roadmap confirmation than on another rerating.

The update came ahead of Q2 results, so the timing matters. If Scorpio X starts showing up more clearly in revenue mix and guidance, late-2026 and 2027 estimates can keep moving higher. If not, the stock could remain richly expected even if the business stays solid.

Astera's Q1 results gave analysts a sturdier basis for higher estimates

Astera's latest quarter looked stronger than a simple beat. The company reported record quarterly revenue of $308.4 million, up 14% quarter over quarter and 93% year over year, with GAAP gross margin at 76.3%. That combination matters because the growth did not come at the obvious expense of product economics.

Management also tied that result to visible product momentum: robust demand for its PCIe 6 portfolio, launch and initial shipments of the Scorpio X-Series, switch coverage expanding from 32 to 320 lanes, and growing engagement around custom and optical solutions. When revenue, margin, and shipment commentary reinforce each other in one quarter, modelers have less reason to treat growth as fragile.

Scorpio X broadens the story beyond retimers

The biggest change in the setup is scope. Earlier bullish arguments could focus heavily on Astera's retimer position. Now the market is also looking at switch content and deeper rack-level opportunity.

Susquehanna specifically pointed to upside from Trn3 and the broader scale-up of deployments beyond the existing retimer opportunity. That shifts the discussion from retimer demand alone to how much connectivity content Astera can capture per rack over time.

That also helps explain why the revision window extends beyond one quarter. Switch-related revenue typically compounds across design wins, first silicon, validations, and larger deployments. Susquehanna framed its update around 2H26 and 2027 forecasts, not just one quarter of momentum.

The stock still has to earn the valuation

The key debate is no longer whether Astera is executing. It is whether execution can keep outrunning expectations.

Susquehanna's $275 price target still implies roughly 8.24% downside from the current price, which suggests the market already expects a lot of this improvement. The factor screen tells a similar story: Revisions 98, Momentum 90, Value 23, and Volatility 6. That reads less like neglected upside and more like a strong narrative already showing up in consensus and price action.

What would strengthen the bull case from here

The next confirmation point is Q2. For the case to get more compelling, investors need another clean quarter that shows:

• revenue growth remains firm
• Scorpio X becomes more visible in results, not just in commentary
• margins stay in the mid-70% range

If those signals hold, the current Neutral can keep moving toward stronger execution. If they slip, the main risk is not business failure but expectations normalizing faster than the stock was built for.